[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,542,272
  • Shares Outstanding, K 40,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,610 K
  • EBIT $ -119 M
  • EBITDA $ -118 M
  • 60-Month Beta -1.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.74
  • Number of Estimates 3
  • High Estimate $-0.67
  • Low Estimate $-0.85
  • Prior Year $-0.65
  • Growth Rate Est. (year over year) -13.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
150.63 +8.35%
on 07/20/26
181.56 -10.11%
on 08/12/26
+13.13 (+8.75%)
since 07/17/26
3-Month
130.00 +25.55%
on 06/02/26
181.56 -10.11%
on 08/12/26
+20.21 (+14.13%)
since 05/15/26
52-Week
60.00 +172.02%
on 08/20/25
200.00 -18.39%
on 02/03/26
+96.58 (+144.95%)
since 08/15/25

Most Recent Stories

More News
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act...

BLTE : 163.21 (+0.25%)
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026...

BLTE : 163.21 (+0.25%)
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 163.21 (+0.25%)
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to...

BLTE : 163.21 (+0.25%)
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 163.21 (+0.25%)
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 163.21 (+0.25%)
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 163.21 (+0.25%)
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 163.21 (+0.25%)
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 163.21 (+0.25%)
Belite Bio Q1 Earnings Call Highlights

Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations...

BLTE : 163.21 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases....

See More

Key Turning Points

3rd Resistance Point 170.94
2nd Resistance Point 168.51
1st Resistance Point 165.86
Last Price 163.21
1st Support Level 160.78
2nd Support Level 158.35
3rd Support Level 155.70

See More

52-Week High 200.00
Last Price 163.21
Fibonacci 61.8% 146.52
Fibonacci 50% 130.00
Fibonacci 38.2% 113.48
52-Week Low 60.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.